Business
Immunome to Present at 2024 Bank of America Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted
About this update from Immunome, Inc.
[{"type":"text","content":" BOTHELL, Wash.--(BUSINESS WIRE)--\nImmunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and Chief Executive Officer, will present at the 2024 Bank of America Healthcare Conference on Wednesday, May 15, 2024 at 10:40 A.M. Pacific Time.\n\n\nInterested parties can access the live audio webcast for this conference from the Investor Relations section of the company’s website at www.immunome.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.\n\n\nAbout Immunome, Inc.\n\n\nImmunome is a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies. Our portfolio pursues each target with a modality appropriate to its biology, including small molecules, ADCs, and radioligand therapies. We believe that pursuing underexplored targets with appropriate drug modalities leads to transformative therapies. Our proprietary memory B cell hybridoma technology allows for the rapid screening and functional characterization of novel antibodies and targets.\n\n\nFor more information, visit www.immunome.com or follow us on Twitter and LinkedIn.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20240508531812/en/\n\nInvestor Contact\nMax Rosett\nInterim Chief Financial Officer\[email protected]\n\n\nSource: Immunome, Inc.","length":3233,"tagName":"div"}]